Identification

Name
Acebutolol
Accession Number
DB01193  (APRD00772)
Type
Small Molecule
Groups
Approved, Investigational
Description

A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.

Structure
Thumb
Synonyms
  • (±)-acebutolol
  • 3'-acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide
  • 5'-butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone
  • Acebutololum
  • Acetobutolol
  • N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide
  • N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide
Product Ingredients
IngredientUNIICASInChI Key
Acebutolol HydrochlorideB025Y34C5434381-68-5KTUFKADDDORSSI-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AcebutololTablet400 mgOralSanis Health Inc2010-02-25Not applicableCanada
AcebutololTablet100 mgOralSanis Health Inc2010-02-25Not applicableCanada
AcebutololTablet200 mgOralSanis Health Inc2010-02-25Not applicableCanada
Acebutolol - 400 - Tab 400mgTablet400 mgOralPro Doc Limitee1996-12-31Not applicableCanada
Acebutolol-100-tab 100mgTablet100 mgOralPro Doc Limitee1996-12-31Not applicableCanada
Acebutolol-200 - Tab 200mgTablet200 mgOralPro Doc Limitee1996-12-31Not applicableCanada
Monitan 100Tablet100 mgOralWyeth Ltd.1995-12-312004-09-13Canada
Monitan 200Tablet200 mgOralWyeth Ltd.1995-12-312007-01-22Canada
Monitan 400Tablet400 mgOralWyeth Ltd.1994-12-312007-01-22Canada
Monitan Tab 200mgTablet200 mgOralWyeth Ltd.1987-12-311996-09-10Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acebutolol HydrochlorideCapsule200 mg/1OralAv Kare, Inc.2009-12-14Not applicableUs
Acebutolol HydrochlorideCapsule200 mg/1OralMarlex Pharmaceuticals Inc2017-10-20Not applicableUs
Acebutolol HydrochlorideCapsule400 mg/1OralMylan Pharmaceuticals1995-04-24Not applicableUs
Acebutolol HydrochlorideCapsule200 mg/1OralAmneal Pharmaceuticals of New York Llc2009-12-01Not applicableUs
Acebutolol HydrochlorideCapsule400 mg/1OralAv Pak2009-12-012016-10-13Us
Acebutolol HydrochlorideCapsule200 mg/1OralAmneal Pharmaceuticals of New York Llc2009-12-01Not applicableUs
Acebutolol HydrochlorideCapsule200 mg/1Oralbryant ranch prepack2009-12-012018-01-10Us
Acebutolol HydrochlorideCapsule200 mg/1OralMylan Pharmaceuticals1995-04-24Not applicableUs
Acebutolol HydrochlorideCapsule200 mg/1OralAv Pak2009-12-01Not applicableUs
Acebutolol HydrochlorideCapsule400 mg/1OralAv Kare, Inc.2009-12-14Not applicableUs
International/Other Brands
Prent (Bayer)
Categories
UNII
67P356D8GH
CAS number
37517-30-9
Weight
Average: 336.4259
Monoisotopic: 336.204907394
Chemical Formula
C18H28N2O4
InChI Key
GOEMGAFJFRBGGG-UHFFFAOYSA-N
InChI
InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
IUPAC Name
N-(3-acetyl-4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)butanamide
SMILES
CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1

Pharmacology

Indication

For the management of hypertension and ventricular premature beats in adults.

Structured Indications
Pharmacodynamics

Acebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. In general, beta-blockers reduce the work the heart has to do and allow it to beat more regularly. Acebutolol has less antagonistic effects on peripheral vascular ß2-receptors at rest and after epinephrine stimulation than nonselective beta-antagonists. Low doses of acebutolol produce less evidence of bronchoconstriction than nonselective agents like propranolol but more than atenolol.

Mechanism of action

Acebutolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Acebutolol blocks these receptors, lowering the heart rate and blood pressure. This drug then has the reverse effect of epinephrine. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.

TargetActionsOrganism
ABeta-1 adrenergic receptor
partial agonist
Human
UBeta-2 adrenergic receptor
partial agonist
Human
Absorption

Well absorbed from the Gl tract with an absolute bioavailability of approximately 40% for the parent compound. In

Volume of distribution
Not Available
Protein binding

26%

Metabolism

Subject to extensive first-pass hepatic biotransformation (primarily to diacetolol).

Route of elimination

Elimination via renal excretion is approximately 30% to 40% and by non-renal mechanisms 50% to 60%, which includes excretion into the bile and direct passage through the intestinal wall.

Half life

The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.

Clearance
Not Available
Toxicity

Symptoms of overdose include extreme bradycardia, advanced atrioventricular block, intraventricular conduction defects, hypotension, severe congestive heart failure, seizures, and in susceptible patients, bronchospasm, and hypoglycemia.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Acebutolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Acebutolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Acebutolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Acebutolol.Experimental
AceclofenacAceclofenac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Acebutolol can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineAcepromazine may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Acebutolol.Approved
AcetohexamideAcebutolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Acetylcholine.Approved
AcetyldigitoxinAcebutolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinAcebutolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Acebutolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Experimental, Investigational
AlaproclateThe serum concentration of Acebutolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Acebutolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Acebutolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
AliskirenAcebutolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Acebutolol.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Acebutolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Acebutolol.Approved
AmbrisentanAcebutolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateAcebutolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineAcebutolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Acebutolol.Approved
AminophyllineAcebutolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneThe therapeutic efficacy of Acebutolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Acebutolol.Approved
AmobarbitalThe serum concentration of Acebutolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Acebutolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Acebutolol.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Acebutolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Acebutolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Acebutolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Acebutolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
ApalutamideThe serum concentration of Acebutolol can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Acebutolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Acebutolol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
ArbutamineAcebutolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Arecoline.Experimental
ArformoterolAcebutolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Acebutolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Acebutolol.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Acebutolol.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Acebutolol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Acebutolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Acebutolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Acebutolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Acebutolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Acebutolol is combined with Azilsartan medoxomil.Approved, Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
BambuterolAcebutolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneThe serum concentration of Acebutolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Acebutolol can be decreased when it is combined with Barbital.Illicit
BarnidipineAcebutolol may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Acebutolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Acebutolol.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Acebutolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Acebutolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Acebutolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Acebutolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Acebutolol.Approved
BepridilAcebutolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantAcebutolol may increase the bradycardic activities of Beractant.Approved
BetaxololBetaxolol may increase the hypotensive activities of Acebutolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Acebutolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Acebutolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Acebutolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Acebutolol.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Acebutolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Acebutolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Acebutolol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Acebutolol.Approved, Investigational
BQ-123Acebutolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Acebutolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Acebutolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Acebutolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Acebutolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Acebutolol.Investigational
BucindololAcebutolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Acebutolol.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Acebutolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acebutolol.Approved
BunazosinAcebutolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Acebutolol.Approved, Investigational
BupranololAcebutolol may increase the hypotensive activities of Bupranolol.Approved
CabergolineAcebutolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Acebutolol.Experimental
CafedrineAcebutolol may increase the hypotensive activities of Cafedrine.Investigational
CalfactantAcebutolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Canagliflozin.Approved
CandesartanAcebutolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Acebutolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Acebutolol.Experimental
CaptoprilAcebutolol may increase the hypotensive activities of Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Acebutolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Acebutolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Acebutolol.Approved, Investigational
CarbutamideAcebutolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Acebutolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Acebutolol.Approved
CarvedilolAcebutolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Acebutolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Celiprolol.Approved, Investigational
CeritinibAcebutolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Acebutolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Acebutolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Acebutolol.Approved, Investigational, Vet Approved
ChlorpropamideAcebutolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Acebutolol.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Acebutolol.Approved
CicletanineAcebutolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilAcebutolol may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Acebutolol.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Acebutolol.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Acebutolol.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Acebutolol.Approved
CloranololAcebutolol may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Acebutolol.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Acebutolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Acebutolol.Vet Approved
CrizotinibAcebutolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Acebutolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
CyclopenthiazideAcebutolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Acebutolol.Approved
CymarinAcebutolol may increase the bradycardic activities of Cymarin.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Acebutolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Acebutolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Acebutolol.Approved
DelaprilAcebutolol may increase the hypotensive activities of Delapril.Experimental
DemecariumDemecarium may increase the bradycardic activities of Acebutolol.Approved
DeserpidineAcebutolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Acebutolol.Approved
DeslanosideAcebutolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Acebutolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Acebutolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Acebutolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Acebutolol.Approved, Investigational
DiethylnorspermineAcebutolol may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Acebutolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
DigitoxinAcebutolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinAcebutolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Acebutolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Acebutolol.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Acebutolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Acebutolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Acebutolol.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Acebutolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Acebutolol.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Acebutolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Acebutolol.Approved
DoxazosinAcebutolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Doxofylline.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Acebutolol.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Acebutolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Acebutolol.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
DuloxetineAcebutolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Acebutolol.Investigational
DyphyllineAcebutolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Acebutolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Acebutolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Acebutolol.Approved
EfonidipineAcebutolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
EnalaprilatAcebutolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Acebutolol.Experimental
EpanololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Nutraceutical, Withdrawn
EphedrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Ephedrine.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Acebutolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Acebutolol.Approved
EpoprostenolAcebutolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanEprosartan may increase the hypotensive activities of Acebutolol.Approved
Ergoloid mesylateAcebutolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineAcebutolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Acebutolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Acebutolol.Experimental
EtilefrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Etilefrine.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
EtoperidoneThe serum concentration of Acebutolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
ExisulindExisulind may decrease the antihypertensive activities of Acebutolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Acebutolol.Experimental
FelodipineFelodipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Acebutolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Acebutolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Acebutolol.Approved
FenoterolThe risk or severity of adverse effects can be increased when Acebutolol is combined with Fenoterol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Acebutolol is combined with Fenozolone.Experimental
FentanylFentanyl may increase the bradycardic activities of Acebutolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Acebutolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Acebutolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Acebutolol.Experimental
Ferulic acidAcebutolol may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Acebutolol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Acebutolol.Approved, Investigational
FingolimodAcebutolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Acebutolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Acebutolol.Experimental
FluoxetineThe serum concentration of Acebutolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Acebutolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
FormoterolAcebutolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Acebutolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Acebutolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Acebutolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Acebutolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Acebutolol.Approved
GitoformateAcebutolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideAcebutolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideAcebutolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAcebutolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAcebutolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneAcebutolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideAcebutolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideAcebutolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Acebutolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Acebutolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Acebutolol.Approved
GuanazodineAcebutolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Acebutolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
GuanoclorAcebutolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzAcebutolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanAcebutolol may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Acebutolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Acebutolol.Experimental
HexamethoniumAcebutolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Acebutolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Acebutolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Acebutolol.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Acebutolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Acebutolol.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Acebutolol.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Hydroxyamphetamine.Approved
HydroxychloroquineThe metabolism of Acebutolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Acebutolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Acebutolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Acebutolol.Approved, Investigational
ImidaprilAcebutolol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Acebutolol.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Acebutolol.Approved
IndacaterolAcebutolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Acebutolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Acebutolol.Approved
IndenololAcebutolol may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Acebutolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Acebutolol.Withdrawn
IndoraminAcebutolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanAcebutolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkAcebutolol may increase the hypoglycemic activities of Insulin Pork.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Acebutolol.Approved, Investigational
IpidacrineIpidacrine may increase the bradycardic activities of Acebutolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Acebutolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Acebutolol.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Acebutolol.Approved, Investigational
IsavuconazoleThe serum concentration of Acebutolol can be increased when it is combined with Isavuconazole.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Acebutolol.Approved
IsoetarineAcebutolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Acebutolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Acebutolol.Approved, Investigational, Withdrawn
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Acebutolol.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acebutolol.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Acebutolol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Acebutolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
IvabradineAcebutolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Acebutolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Acebutolol.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Acebutolol.Approved
LabetalolAcebutolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineAcebutolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideAcebutolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CAcebutolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideAcebutolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Acebutolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Acebutolol.Approved, Investigational
LevodopaAcebutolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Acebutolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
LevosalbutamolAcebutolol may decrease the bronchodilatory activities of Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Acebutolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Acebutolol.Approved, Vet Approved
LinezolidLinezolid may increase the hypertensive activities of Acebutolol.Approved, Investigational
LinsidomineAcebutolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Acebutolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Acebutolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Acebutolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Acebutolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
LucinactantAcebutolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumacaftorThe serum concentration of Acebutolol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
MacitentanAcebutolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Acebutolol.Approved
MalathionMalathion may increase the bradycardic activities of Acebutolol.Approved, Investigational
ManidipineAcebutolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Acebutolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Acebutolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Acebutolol.Approved
MefenorexThe risk or severity of adverse effects can be increased when Acebutolol is combined with Mefenorex.Experimental
MefloquineMefloquine may increase the bradycardic activities of Acebutolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Acebutolol.Approved, Investigational
MephentermineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Mephentermine.Approved
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Acebutolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Acebutolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
MetahexamideAcebutolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Withdrawn
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Acebutolol.Approved, Investigational
MethacholineAcebutolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Acebutolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Acebutolol.Approved
MethohexitalThe serum concentration of Acebutolol can be decreased when it is combined with Methohexital.Approved
MethoserpidineAcebutolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Acebutolol.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acebutolol.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Acebutolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Acebutolol.Approved, Investigational
MethylergometrineAcebutolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Acebutolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinAcebutolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololAcebutolol may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Acebutolol.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Acebutolol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Acebutolol.Approved, Investigational
MetyrosineAcebutolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilAcebutolol may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineAcebutolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Acebutolol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Acebutolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Acebutolol.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Acebutolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Acebutolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Acebutolol.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Acebutolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Acebutolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Acebutolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Acebutolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Acebutolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
MuzolimineAcebutolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Acebutolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Acebutolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Acebutolol.Approved
NadololAcebutolol may increase the hypotensive activities of Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Acebutolol.Approved
NaftopidilAcebutolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
NebivololAcebutolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Acebutolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Acebutolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Acebutolol.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Acebutolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Acebutolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Acebutolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Acebutolol.Approved
NiguldipineAcebutolol may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineAcebutolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Acebutolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Acebutolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Acebutolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Acebutolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Acebutolol.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Acebutolol.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Acebutolol.Approved, Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
NylidrinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nylidrin.Approved
ObinutuzumabAcebutolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Acebutolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Acebutolol.Approved, Investigational
OleandrinAcebutolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Acebutolol.Approved, Investigational
OlodaterolAcebutolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Acebutolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Acebutolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Acebutolol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Acebutolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Acebutolol.Vet Approved
OuabainAcebutolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Acebutolol.Approved
OxprenololAcebutolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Acebutolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Acebutolol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Acebutolol.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Acebutolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Acebutolol.Approved
PargylinePargyline may increase the hypotensive activities of Acebutolol.Approved
ParoxetineThe serum concentration of Acebutolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
PasireotideAcebutolol may increase the bradycardic activities of Pasireotide.Approved
PenbutololAcebutolol may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe serum concentration of Acebutolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Acebutolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Acebutolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Acebutolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Acebutolol.Approved
PeruvosideAcebutolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Acebutolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Acebutolol.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol.Approved, Illicit
PhenobarbitalThe serum concentration of Acebutolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Acebutolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Acebutolol.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Acebutolol.Approved, Illicit
PhentolaminePhentolamine may increase the hypotensive activities of Acebutolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Acebutolol.Approved, Vet Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Acebutolol.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Acebutolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Acebutolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Acebutolol.Approved
PindololPindolol may increase the hypotensive activities of Acebutolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Acebutolol.Approved, Investigational
PirbuterolAcebutolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Acebutolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Acebutolol.Experimental
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Acebutolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Acebutolol.Withdrawn
Platelet Activating FactorAcebutolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideAcebutolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaAcebutolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Acebutolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Acebutolol.Experimental, Investigational
PrazosinAcebutolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Acebutolol is combined with Prenalterol.Experimental
PrimaquineThe metabolism of Acebutolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Acebutolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Acebutolol is combined with Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Acebutolol.Experimental
PromazinePromazine may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
PropafenoneThe serum concentration of Acebutolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
PropiopromazinePropiopromazine may increase the hypotensive activities of Acebutolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Acebutolol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Acebutolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Acebutolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Acebutolol.Experimental
ProscillaridinAcebutolol may increase the bradycardic activities of Proscillaridin.Experimental
ProtokylolAcebutolol may decrease the bronchodilatory activities of Protokylol.Approved, Vet Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Acebutolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Acebutolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Acebutolol.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Acebutolol.Approved
RacepinephrineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
RamiprilRamipril may increase the hypotensive activities of Acebutolol.Approved
RanolazineThe serum concentration of Acebutolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Acebutolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Acebutolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Acebutolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Acebutolol.Approved
RescinnamineAcebutolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Acebutolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Acebutolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Acebutolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Acebutolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Acebutolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Acebutolol.Approved, Investigational
RiociguatAcebutolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneAcebutolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Acebutolol.Approved, Investigational
RituximabAcebutolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineAcebutolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Acebutolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Acebutolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Acebutolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Acebutolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Acebutolol.Withdrawn
SalbutamolAcebutolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Acebutolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Vet Approved
SalmeterolAcebutolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Acebutolol.Approved
SaprisartanAcebutolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe serum concentration of Acebutolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Acebutolol.Approved, Investigational, Vet Approved
SelexipagAcebutolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Acebutolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Acebutolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Acebutolol.Investigational
SertralineThe serum concentration of Acebutolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acebutolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Acebutolol.Approved, Investigational
SilodosinAcebutolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanAcebutolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Acebutolol.Approved
SpiraprilAcebutolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Acebutolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Acebutolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Acebutolol.Approved, Investigational
SufentanilSufentanil may increase the bradycardic activities of Acebutolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Acebutolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Acebutolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Acebutolol.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Synephrine.Experimental
TacrineTacrine may increase the bradycardic activities of Acebutolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Acebutolol.Approved, Investigational
TalinololAcebutolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinAcebutolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Acebutolol.Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Acebutolol.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Acebutolol.Approved, Investigational
TemocaprilAcebutolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Acebutolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Acebutolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Acebutolol.Vet Approved
TerazosinAcebutolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Acebutolol.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Acebutolol.Approved
TerlipressinAcebutolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineAcebutolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Acebutolol.Approved, Investigational, Withdrawn
TheodrenalineAcebutolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineAcebutolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Acebutolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Acebutolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Acebutolol.Withdrawn
ThiopentalThe serum concentration of Acebutolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Acebutolol.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Acebutolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Acebutolol.Approved
TiboloneAcebutolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenAcebutolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Acebutolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Acebutolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
TofacitinibTofacitinib may increase the bradycardic activities of Acebutolol.Approved, Investigational
TolazamideAcebutolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
TolbutamideAcebutolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Acebutolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Acebutolol.Approved
TolonidineAcebutolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Acebutolol.Approved
TorasemideTorasemide may increase the hypotensive activities of Acebutolol.Approved
TramazolineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tramazoline.Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Acebutolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Acebutolol.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Acebutolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Acebutolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Acebutolol.Approved, Investigational, Nutraceutical
TretoquinolThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Acebutolol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Acebutolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Acebutolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Acebutolol.Approved, Vet Approved
TrimazosinAcebutolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Acebutolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Acebutolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Acebutolol.Approved
TyramineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tyramine.Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Acebutolol.Approved, Investigational
UnoprostoneAcebutolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilAcebutolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Acebutolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Acebutolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Varenicline.Approved, Investigational
VemurafenibThe serum concentration of Acebutolol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Acebutolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Acebutolol.Approved
VilanterolAcebutolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineAcebutolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineAcebutolol may increase the hypotensive activities of Vinpocetine.Investigational
XipamideAcebutolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Acebutolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Acebutolol can be increased when it is combined with Zimelidine.Withdrawn
ZofenoprilAcebutolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Acebutolol.Withdrawn
Food Interactions
  • Take without regard to meals; absorption rate and maximal concentration are slightly reduced but the extent of absorption is not affected.

References

Synthesis Reference
US3857952
General References
Not Available
External Links
Human Metabolome Database
HMDB0015324
KEGG Drug
D02338
KEGG Compound
C06803
PubChem Compound
1978
PubChem Substance
46509113
ChemSpider
1901
BindingDB
25755
ChEBI
2379
ChEMBL
CHEMBL642
Therapeutic Targets Database
DAP000484
PharmGKB
PA448011
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Acebutolol
ATC Codes
C07AB04 — AcebutololC07BB04 — Acebutolol and thiazides
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension) / Vascular Diseases1
3TerminatedTreatmentHemangiomas1
4CompletedTreatmentHealthy Volunteers1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Alphapharm Party Ltd.
  • Amneal Pharmaceuticals
  • Bryant Ranch Prepack
  • Caremark LLC
  • Kaiser Foundation Hospital
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Patheon Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Professional Co.
  • Promius Pharma
Dosage forms
FormRouteStrength
CapsuleOral200 mg/1
CapsuleOral400 mg/1
TabletOral400 mg
TabletOral100 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Acebutolol hcl powder7.08USD g
Sectral 400 mg capsule4.48USD capsule
Sectral 200 mg capsule3.37USD capsule
Acebutolol HCl 400 mg capsule1.39USD capsule
Acebutolol 400 mg capsule1.34USD capsule
Sectral 400 mg Tablet1.11USD tablet
Acebutolol HCl 200 mg capsule1.05USD capsule
Acebutolol 200 mg capsule1.01USD capsule
Sectral 200 mg Tablet0.56USD tablet
Acebutolol 400 mg Tablet0.51USD tablet
Apo-Acebutolol 400 mg Tablet0.51USD tablet
Mylan-Acebutolol (Type S) 400 mg Tablet0.51USD tablet
Mylan-Acebutolol 400 mg Tablet0.51USD tablet
Novo-Acebutolol 400 mg Tablet0.51USD tablet
Nu-Acebutolol 400 mg Tablet0.51USD tablet
Rhotral 400 mg Tablet0.51USD tablet
Sectral 100 mg Tablet0.37USD tablet
Acebutolol 200 mg Tablet0.26USD tablet
Apo-Acebutolol 200 mg Tablet0.26USD tablet
Mylan-Acebutolol (Type S) 200 mg Tablet0.26USD tablet
Mylan-Acebutolol 200 mg Tablet0.26USD tablet
Novo-Acebutolol 200 mg Tablet0.26USD tablet
Nu-Acebutolol 200 mg Tablet0.26USD tablet
Rhotral 200 mg Tablet0.26USD tablet
Acebutolol 100 mg Tablet0.17USD tablet
Apo-Acebutolol 100 mg Tablet0.17USD tablet
Mylan-Acebutolol (Type S) 100 mg Tablet0.17USD tablet
Mylan-Acebutolol 100 mg Tablet0.17USD tablet
Novo-Acebutolol 100 mg Tablet0.17USD tablet
Nu-Acebutolol 100 mg Tablet0.17USD tablet
Rhotral 100 mg Tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)136-138Merck Index 13
water solubility259 mg/LNot Available
logP1.71HANSCH,C ET AL. (1995)
Caco2 permeability-5.83ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.172 mg/mLALOGPS
logP1.43ALOGPS
logP1.53ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.91ChemAxon
pKa (Strongest Basic)9.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area87.66 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity94.87 m3·mol-1ChemAxon
Polarizability38.51 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7378
P-glycoprotein inhibitor INon-inhibitor0.8557
P-glycoprotein inhibitor IINon-inhibitor0.8664
Renal organic cation transporterNon-inhibitor0.9466
CYP450 2C9 substrateNon-substrate0.8102
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5752
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8721
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9639
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.849
BiodegradationNot ready biodegradable0.8538
Rat acute toxicity2.0487 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9821
hERG inhibition (predictor II)Non-inhibitor0.8555
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Acetophenones / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Propargyl-type 1,3-dipolar organic compounds / Dialkylamines
show 4 more
Substituents
Alkyl-phenylketone / Acetophenone / Benzoyl / Phenol ether / Aryl alkyl ketone / Phenoxy compound / Alkyl aryl ether / Monocyclic benzene moiety / Benzenoid / 1,2-aminoalcohol
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid amide, secondary amino compound, ether, aromatic amide, ethanolamines, propanolamine (CHEBI:2379)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. van den Meiracker AH, Man in 't Veld AJ, Fischberg DJ, Molinoff PB, van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA: Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density. J Cardiovasc Pharmacol. 1988 Apr;11(4):413-23. [PubMed:2453744]
  2. Abrahamsson T: Characterization of the beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70. Eur J Pharmacol. 1989 May 2;164(1):121-8. [PubMed:2568935]
  3. Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148]
  2. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496]
  3. Lima JJ: Relationship between beta adrenoceptor occupancy and receptor down-regulation induced by beta antagonists with intrinsic sympathomimetic activity. J Recept Signal Transduct Res. 1996 Sep-Nov;16(5-6):357-72. [PubMed:8968966]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  2. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513]

Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:04